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Background: Integrating patient preferences in Health Technology Assessment (HTA) is argued to improve uptake, adherence,
and patient satisfaction. However, how to elicit and incorporate these preferences in HTA in a systematic and scientiﬁcally
valid manner is subject to debate.
Objective: This article provides a systematic review of the challenges to integrating patient preferences in HTA that have been
raised in the literature about patient preferences in HTA.
Methods: A systematic review of articles published between 2013 and 2017 addressing challenges to the integration of patient
preferences in HTAwas conducted in 7 databases. All issues with respect to the integration of patient preferences in HTAwere
extracted and divided into 5 categories: conceptual, normative, procedural, methodological, and practical issues. The issues
were ranked according to how often they were mentioned.
Results: Of 2147 retrieved articles, 67 were included in the analysis. Thirty-seven unique research issues were identiﬁed. In
the majority of the articles, methodological issues were posed (82%), followed by procedural (73%), normative (51%),
practical (24%), and conceptual (9%) issues. Frequently posed methodological issues concerned preference heterogeneity
and choice of method. Common procedural issues concerned how to evaluate the impact of preference studies and their
degree of being evidence based.
Conclusions: This article provides an overview of issues with respect to the integration of patient preferences in HTA
procedures. Most issues were of a methodological or procedural nature; yet, the large number of different issues points to the
overall importance of further researching the different aspects concerned with patient preferences in HTA. Through its
ranking of how many articles mention particular issues, this article proposes an implicit research agenda.
Keywords: health preference research, Health Technology Assessment, patient engagement, patient preferences, research
agenda, systematic review.
VALUE HEALTH. 2019; 22(11):1318–1328Introduction
Health Technology Assessment (HTA) informs reimbursement
and coverage decisions on how to allocate healthcare resources
to different health technologies by carefully assessing the costs
and beneﬁts of health interventions.1 With the increasing focus
on patient preferences in clinical practice guidelines,2–4 academic
research,5,6 and regulatory decision making,7–9 it is important
that HTA not fall behind.10 The US Food and Drug Administration
deﬁnes patient preference information as “qualitative or
quantitative assessments of the relative desirability orss correspondence to: Samare P.I. Huls, MSc, Erasmus School of Health Poli
am, The Netherlands 0031 10 408 8860. Email: huls@eshpm.eur.nl
15 - see front matter Copyright ª 2019, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/lic
doi.org/10.1016/j.jval.2019.04.1930acceptability to patients of speciﬁed alternatives or choices
among outcomes or other attributes that differ among alternative
health interventions.”11 In this context, qualitative assessments
usually refer to exploring patient preferences and quantitative
assessments for eliciting patient preferences. Not aligning the
assessment of health intervention costs and beneﬁts with patient
preferences can cause adherence to be very different than
expected, and it can explain why many health interventions that
have developed throughout the medical product life cycle end up
not being used.12 Other arguments for integrating patient
preferences in HTA are that it is considered ethical to listen to thecy & Management, Erasmus University Rotterdam, PO Box 1738, 30000 DR,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
SYSTEMATIC LITERATURE REVIEW 1319patient voice,13,14 it will increase patient satisfaction,14,15 and that
HTA decision making will be more informed and more
transparent with the inclusion of patient-relevant value
judgments and experiential data.13–17
Although the US Food and Drug Administration has provided
guidance on how to use patient preference information in
beneﬁt-risk assessments,11 HTA is still lagging behind. Patients are
increasingly being involved in the HTA decision-making
process,18,19 but how to elicit and incorporate patient
preferences in a systematic and scientiﬁcally valid manner is still
subject to debate. For example, Weernink et al.20 could not ﬁnd a
method that performed well from a statistical and patient burden
point of view. Janssen et al.21 suggested further researching
validity and reliability tests for quantitative preference methods.
Facey et al.22 discussed whether and how qualitative, and
quantitative, patient preference studies could be considered
robust scientiﬁc evidence. Hansen and Lee17 questioned the
validity of qualitative research methods. In a recently published
editorial, Mott10 stated that HTA needs “substantive changes” to
catch up with regulatory decision making in the incorporation of
patient preferences. He mainly questioned how to weigh patient
preference information in current HTA procedures. Facey et al.23
highlighted the “substantial challenges to realizing the goal of
informing evidence-based patient-centered policy.” The variety of
open questions concerning patient preferences in HTA raised by
different researchers suggests the need for a comprehensive
overview of all challenges in the ﬁeld. Therefore, the objective of
this article is to provide a systematic review of the challenges to
integrating patient preferences in HTA raised by literature. By
doing so, an implicit research agenda is proposed.Methods
Study Design
To identify open questions concerning the use of patient
preferences in HTA, the following study design was used.
First, literature about patient preferences in HTA was identiﬁed.
Second, the study characteristics of the included literature were
elicited. Third, issues related to the integration of patient
preferences in HTA, as raised in the literature, were derived. Last,
the issues were categorized according to thematic differences and
similarities. The results were analyzed on 3 different levels of
categorization, namely from broad to speciﬁc: “categories,”
“topics,” and “issues.” An illustration of the study design can be
found in Figure 1.Figure 1. Study design. The 3 different levels of categorization, from
issues were subdivided into topics; topics (and their issues) were alsoIdentiﬁcation of Literature
To identify literature about patient preferences in HTA, we
conducted a systematic review using the databases Embase,
Medline Ovid, Web of Science, Scopus, Cochrane CENTRAL,
CINAHL EBSCOhost, and Google Scholar. The search terms can
be found in Appendix A in supplementary materials found at
https://doi.org/10.1016/j.jval.2019.04.1930.
Articles were deemed eligible if they met the following 6
inclusion criteria. The studies had to concern patient preferences,
had to concern HTA, and had to discuss at least 1 issue concerning
the integration of patient preferences in HTA. Further, the articles
had to be English-language articles, the full text had to be
available, and the articles had to be published between 2013 and
2017 because recent publication is inherent to providing a
contemporary overview.
After excluding duplicates and articles outside the
relevant publication years, 2 of the researchers (S.H. and C.W.)
independently reviewed the remaining titles and abstracts for
eligibility. If at least 1 of the researchers determined that an article
met the eligibility criteria based on title and abstract screening, a
full-text screening was done by the researchers. If no consensus
could be reached about the eligibility of the full text, a third
researcher (E.B.G.) was consulted. The review was conducted in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Statement.24
Description of Study Characteristics
For all eligible articles, 6 study characteristics were extracted.
Extracted data included the country in which the ﬁrst author was
employed, whether the study was a theoretical or applied study,
the medical context (ie, general or disease-speciﬁc) in which the
study was conducted, and whether the article concerned
qualitative (exploring) or quantitative (eliciting) patient
preferences. In addition, we extracted which type of stakeholders
raised the issue (eg, respondents or the authors) and for which
type of stakeholders the issue was relevant (eg, patients, HTA
bodies, or academics). Data were extracted by 1 researcher, after
which 2 other researchers validated the ﬁndings.
Elicitation of Issues
Issues concerning the integration of patient preferences in HTA
were extracted from the literature in the broadest sense
(ie, questions, concerns, barriers, facilitators, and areas for further
research). All study-speciﬁc elements were deleted from the
extracted issues to allow for comparison of the issues acrossbroad to speciﬁc, were “categories,” “topics,” and “issues.” Elicited
subdivided into categories.
Figure 2. Study selection.
Articles identified by database
searching
(N = 2,147)
Articles screened (N = 375)
Full-text articles assessed for 
eligibility (N = 262)
Full-text articles excluded
 (N = 195):
Excluded articles outside of 
relevant publication years
(N = 688)
Excluded duplicate articles 
(N = 1,084)
Excluded articles based on title 
and abstract (N = 113)
- No patient preferences (N = 74)
- No HTA (N = 25)
- No integration (N = 6)
- No recommendation (N = 47)
- Other (N = 16)
- >1 exclusion criterion (N = 27)
Studies included in systematic
review (N = 67)
1320 VALUE IN HEALTH NOVEMBER 2019studies. Data were extracted by 1 researcher, followed by
conﬁrmation of 2 other researchers.
Categorization of Issues
Two researchers (S.H. and C.W.) performed a 3-level
categorization of the elicited issues, and a third researcher was
consulted if no consensus could be reached. The 3 different levels,
from broad to speciﬁc, were “categories,” “topics,” and “issues.”
Issues were subdivided into topics; topics (and their issues) werealso subdivided into categories. Again, an illustration of the study
design is presented in Figure 1. To enhance consistency of the
categorization process, we deﬁned, before analysis, whether a
research issue would fall into only 1 category or topic,
respectively. Consensus thus had to be reached on which category
or topic best described the issue. As in Utens et al.,25 we used the
following 5 categories as the broadest level of categorization:
conceptual, normative, procedural, methodological, and practical
issues. Conceptual issues relate to the deﬁnition and
characterization of patient preferences. Normative issues concern
Table 1. Study characteristics—summary.
Item N = 67* %†
Country of origin Canada 13 19
United Kingdom 13 19
Germany 10 15
United States 8 12
Australia 7 10
The Netherlands 6 9
Other 10 15
Type of study Theoretical 51 76
Application 15 22
Both 1 1
Medical context General 44 66
Disease speciﬁc 23 34
Preference
elicitation
Qualitative 31 46
Quantitative 17 25
Both 9 13
Not deﬁned 10 15
Issue raised
by stakeholder
Authors and
cited authors
52 78
Respondents:
HTA professionals
5 7
Respondents: Patients 4 6
Respondents: Other 6 9
Issue relevant
for stakeholder
HTA professionals
and academics
34 51
HTA professionals 23 34
Other 10 15
HTA indicates Health Technology Assessment.
*Absolute number of articles
†Relative number of articles (as % of total of 67 articles). Percentages may not
add to 100 because of rounding error.
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Procedural issues relate to how to integrate patient preferences
into the existing procedures of HTA. Methodological issues
address establishing good and accurate research practice on the
topic. Practical issues address all other concerns of a practical
nature such as time and money constraints. The topics were the
second level of categorization. Unlike the categories, topics were
not predeﬁned and were established using backward induction.
The issues were grouped according to thematic similarities and
differences; the exact name of the topic was determined after the
issues were grouped. Included in the third level of categorization
were the issues themselves. The categorized data were analyzed in
2 different ways. First, to give insight into the variety of issues in
each category and topic, respectively, the number of issues in each
category or topic (as % of the total number of issues) was
established. Second, to measure frequency of occurrence of the
issues, the number of articles that mentioned each issue (as % of
total number of articles) was analyzed.
Results
Identiﬁcation of Literature
The database search identiﬁed 2147 articles, of which
375 unique articles published in 2013 to 2017 were screened.
Sixty-seven articles met the inclusion criteria and were subject to
data extraction and analysis (Fig. 2).
Description of Study Characteristics
For most of the articles containing issues regarding patient
preference in HTA, the ﬁrst authors worked on behalf of
organizations/universities in Canada (n = 13; 19%), the
United Kingdom (n = 13; 19%), and Germany (n = 10; 15%) (Table 1).
Othercommoncountriesoforiginwere theUnitedStates (n=8;12%),
Australia (n =7; 10%), and TheNetherlands (n=6; 9%). Three quarters
of the articles (51 of 67 articles) discussed the integration of patient
preferences in HTA theoretically rather than actually conducting a
preference study.Almost twothirdsof the articles (n=44) concerned
a general medical context rather than a disease-speciﬁc context.
Thirty-one articles concerned the qualitative elicitation of
preferences (46%), whereas 17 concerned quantitative preference
elicitation (25%), 9 concerned both (13%), and 10 did not specify
(15%).
Many of the research issues were raised by the authors or
authors cited in the articles (n = 52; 78%). The vast majority of ﬁrst
authors (73%) worked in academia; the remainder worked for a
variety of organizations (eg, patient organizations, HTA agencies,
and private consultants). In the remainder of articles where study
respondents were speciﬁcally asked about the advancement of
patient preference integration in HTA (n = 15, 22%), respondents
were HTA professionals (n = 5), patients (n = 4), and a variety of
other respondents (eg, healthcare professionals, caregivers, and
policy makers, n = 6). Most of the issues were relevant for HTA
professionals and academics (n = 34; 51%). Other issues were
relevant for HTA professionals only (n = 23; 34%) or for a variety of
HTA professionals, clinical guideline developers, patients, patient
organizations, or clinicians (n = 10; 15%). Table 1 summarizes
these study characteristics; a more elaborate overview of the
study characteristics per article is presented in Appendix B in the
supplementary materials found at https://doi.org/10.1016/j.jval.2
019.04.1930.
Categorization of Issues
Across the 5 categories of identiﬁed issues, 16 topics and 37
unique research issues were identiﬁed from the total selection ofarticles. The issues were the most speciﬁc level of categorization.
These were subdivided into topics. In turn, the topics were
subdivided into categories. Table 2 presents a broad overview of
the research categories and topics. Table 3 presents the most
speciﬁc level, namely, the issues. The analysis of the 3 levels of
categorization is discussed ranging from broad to speciﬁc.
Categories of identiﬁed issues
Of the 37 issues, 1 was conceptual (3%), 5 were normative
(14%), 9 were procedural (24%), 18 were methodological (49%), and
4 were of a practical nature (11%) (Fig. 3). In terms of how often
the issues were mentioned, methodological issues arose relatively
often in the literature—namely, in 55 of 67 articles (82%).
Procedural issues were also mentioned frequently (n = 49; 73%).
Normative issues were raised relatively less frequently (n = 34;
51%), followed by practical issues (n = 16; 24%) and conceptual
issues (n = 6; 9%).
Topics of identiﬁed issues
The 16 research topics that were extracted can be found in
Table 2. Each of these topics contains between 1 and 4 issues. The
establishment of a taxonomy for patient preference studies was
the only conceptual topic that was raised. It was raised in 6 of the
Table 2. Relative occurrence of issues, per category of issues
and per topic of issues.
Category Topic # Issues # Mentions
N = 37* %† N = 67* %†
Conceptual 1 3 6 9
Taxonomy 1 3 6 9
Normative 5 14 34 51
Whose preferences 4 11 26 39
Relevance of
preferences
1 3 11 16
Procedural 9 24 49 73
Weight 3 8 21 31
Impact 1 3 21 31
Patient education 3 8 20 30
Evidence based 1 3 17 25
HTA stage 1 3 16 24
Methodological 18 49 55 82
Choice of method 3 8 30 45
Internal validity 3 8 24 36
Generalizability 4 11 19 28
Sample selection 1 3 15 22
External validity 2 5 9 13
Patient characteristics 2 5 8 12
Reliability 3 8 7 10
Practical 4 11 16 24
Resources 4 11 16 24
HTA indicates Health Technology Assessment.
*Absolute number of issues identiﬁed and absolute number of articles
mentioning each issue.
†Relative number of issues (as % of 37 issues) and relative number of articles
mentioning each issue (as % of 67 articles). Percentages might not add up to
100% because most studies mentioned multiple issues or because of rounding
error.
1322 VALUE IN HEALTH NOVEMBER 201967 articles (9%; eg, Utens et al.,25 Brooker et al.,26 and DeJean
et al.27). Normative topics included whose preferences to elicit and
the relevance of preference studies to patients. Whose preferences
to elicit was mentioned most—namely, in 26 of the 67 articles
(39%; eg, Rashid et al.,28 Gagnon et al.,29 and Buck et al.30).
Procedural topics concerned what weight to give patient
preferences in current HTA procedures, how to evaluate impact,
how to educate patients in preparation for preference studies,
whether and how patient preferences are evidence based, and in
which HTA stage to incorporate patient preferences. The most
often mentioned procedural topics were how to weight preference
studies in comparison to or in addition to current ethical, clinical,
and cost-effectiveness (quality adjusted life year [QALY])
procedures (n = 21; 31%; eg, Dirksen,14 Mühlbacher and
Kaczynski,31 and Mühlbacher and Sadler32) and how to evaluate
the impact of preference studies on HTA decision making (n = 21;
31%; eg, Dipankui et al.,33 Kreis and Schmidt,34 and Abelson
et al.35). Methodological topics concerned choice of method,
internal and external validity, reliability, generalizability, and
which patient characteristics affect preferences and how.
The most prevailing methodological topic was choice of method
(n = 30; 45%; eg, Utens et al.,36 Wortley et al.,37 and Brereton
et al.38), followed by internal validity (n = 24; 36%; eg, Brookeret al.,26 Wahlster et al.,39 and Danner et al.40). The only practical
topic that was raised concerned resource constraints in
conducting preference studies, which was mentioned in 16
of the 67 articles (24%; eg, Utens et al.,25 Hailey et al.,41 and
Single et al.42).
Issues
Table 3 gives an overview of the 37 unique research issues and
their frequency of being mentioned. The most frequently posed
normative issues concerned whether the preferences of
representatives of patient organizations represent the preferences
of a broader set of individuals (n = 13; 19%; eg, Rashid et al.,28
Gagnon et al.,29 and Buck et al.30) as well as whose preferences
should be elicited (n = 12; 18%; eg, Kreis et al.,43 Mott and
Najafzadeh,44 and Thokala et al.45) and whether patient-relevant
outcomes and processes should be accounted for in preference
studies and how this should be done (n = 11; 16%; eg, Evers et al.,46
Mühlbacher et al.,47 and Berglas et al.48). The most
frequently posed issue of a procedural nature was how to
evaluate the impact of preference studies (n = 21; 31%; eg,
Dipankui et al.,33 Kreis and Schmidt,34 and Abelson et al.35),
followed by whether preference studies can be considered robust
scientiﬁc evidence (n = 17; 25%; eg, Iskrov and Stefanov,49
Moreira,50 and Tordrup et al.51) and in which HTA stage to
incorporate them (n = 16; 24%; eg, Hämeen-Anttila et al.,52 Weeks
et al.,53 and Husereau et al.54). The most frequently raised
methodological issues were about which methods to use for
preference elicitation (n = 29; 43%; eg, Utens et al.,36 Wortley
et al.,37 and Brereton et al.38) and about heterogeneity in
preferences (n = 18; 27%; eg, Wahlster et al.,39 Di Paolo et al.,55 and
Doctor and MacEwan56). The most frequently mentioned practical
issues with conducting preference studies were cost constraints
(n = 13; 19%; eg, Wortley et al.,37 Mossman et al.,57 and Kievit
et al.58) and time constraints (n = 11; 16%; eg, Buck et al.,30
Brereton et al.,59 and Scott and Wale60).
Discussion
In this study, from a selection of 67 articles, we identiﬁed 37
unique research issues that concern the integration of patient
preferences in HTA. In most of the articles, methodological issues
were raised (82%), followed by procedural (73%), normative (51%),
practical (24%), and conceptual (9%) issues. Frequently posed
methodological issues were about preference heterogeneity and
choice of method. Common procedural issues concerned how to
evaluate the impact of preference studies and their degree of
being evidence based.
The relatively large number of unique issues shows that
patient preference integration is by and large a relevant topic to be
researched. This review includes theoretical and applied studies
and includes studies in numerous medical contexts from various
countries. Furthermore, the identiﬁed issues relate to qualitative
(exploring) and quantitative (eliciting) preference methods that
might vary in rigorousness and addressability depending on the
research question concerning patient preferences in HTA. Given
the variety of study characteristics, this review provides a
comprehensive research agenda that is relevant for multiple
stakeholders. The issues in the articles were relevant for HTA
professionals, academic researchers, clinical guideline developers,
patients, patient organizations, and/or clinicians. Nonetheless, the
majority of the issues were raised by academic authors of the
articles, and the articles provide little guidance on how to address
the issues. Hence, we believe that to reach consensus on the way
forward, involvement, coordination, and collaboration among the
different stakeholders is warranted.
Table 3. Three-level categorization and relative occurrence of issues.
Category Topic # Issue N = 67* %† Article(s)
Conceptual
Taxonomy 1. How should we deﬁne patient
preferences and subsequently
ﬁnd and retrieve patient
preference studies?
6 9 25–28,36,49
Normative
Whose
preferences
1. Do preferences of representatives
of patient organizations/advocacies
represent preferences of a broader
set of individuals?
13 19 21,29,30,43,52,
57,59,60,62,64,82–84
2. Whose preferences should
be elicited (eg, patients with or
without treatment experience,
carers, patient representatives)?
12 18 25,31,33,34,
43–45,64,68,82,84,85
3. Are patient preferences
inﬂuenced by external factors
(eg, media, family, or
pharmaceutical companies)?
7 10 14,28,29,57,63,64,83
4. How can preferences
from various samples
(eg, clinicians, carers, and patients)
be synthesized to be of value as a whole?
3 4 46,53,85
Relevance 1. What are patient-relevant
outcomes (ie, health vs well-being),
and should preference studies
also focus on process?
11 16 14,25,36,
46–48,58,65,81,86,87
Procedural
Weight 1. How should preference
studies be evaluated in
comparison/addition to clinical
and economic evaluation studies?
15 22 14,25,27,29,31,
36,38,39,60,64,
65,82,84,88,89
2. How can preference studies
add to or replace the QALY paradigm?
5 7 14,32,36,51,75
3. How should ethical issues
concerning patient
preferences be weighed in HTA?
4 6 13,42,60,63
Impact 1. How can we evaluate the
impact of patient preferences
studies on HTA decision making?
21 31 14,21,25,28,29,31,
33–35,37,43,49,52,53,
57,60,62,68,80,82,90
Patient education 1. How can patients be
sufﬁciently trained to perform HTA studies?
14 21 21,29,30,43,52,55,
59,60,63,64,68,82,87,91
2. How can communication
between researchers and
patients be aligned in preference studies?
6 9 21,29,30,60,82,87
3. How should patients and
caregivers be informed
about HTA studies and
the possibility of being involved?
12 19 37,46,52,53,60,
64,65,68,81,82,91,92
Evidence based 1. How is and should
the quality and transparency
of patient preference studies
be assessed to be considered
robust scientiﬁc evidence?
17 25 14,21,28,33,38,43,
46,49–51,58,59,63,
64,75,84,91
HTA stage 1. In which context and
stage of HTA should preferences
be used to inform decision making?
16 24 25,29,30,34,46,
48,52–54,62,65,
84,86,88,90,91
Methodological
Choice of
method
1. Which methods are
preferable for eliciting preferences?
29 43 14,25–27,29,31,
32,34,36–40,45,51,
52,59,61,64,68,75,81,
84,85,90,91,93–95
continued on next page
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Table 3. Continued
Category Topic # Issue N = 67* %† Article(s)
2. When should we use
quantitative (eliciting)
versus qualitative (exploring)
research methods for
patient preference studies?
3 4 14,25,26
3. Which methods to elicit
patient preferences are
preferable in which stage of HTA?
2 3 29,62
Internal
validity
1. How do preferences on
an individual level differ from
those on a collective level
(ie, preference heterogeneity)?
18 27 21,32,36,38–40,44,
47,55,56,58,60,
65,87,89,95–97
2. How does framing affect preferences? 4 6 26,31,40,66
3. How can validity of
preference studies be tested?
1 1 47
Reliability 1. How stable are preferences over time? 4 6 14,47,48,81
2. How consistent are
individuals in preference
studies, how does this affect
results, and how should inconsistent
responses be handled?
3 4 21,40,47
3. How should uncertainty in
patient preferences be modeled?
1 1 31
Generalizability 1. How representative are
preferences from the recruited
sample for the entire population?
9 13 21,28,34,47,59,60,64,68,85
2. Can preference studies
be transferred across
diseases and contexts
(ie, as a generic instrument)?
7 10 14,25,33,39,46,51,81
3. Can preference studies
be transferred across
countries/sociocultural groups?
4 6 38,47,59,92
4. How representative are
preferences for a singular
intervention compared to
when the intervention is
administered alongside other interventions?
2 3 48,81
Sample
selection
1. How (ie, via which
channels and based on
which characteristics)
should the sample be selected?
15 22 28–30,41,43,46,
52,53,59,64,66,
68,82,90,98
External
validity
1. What is the external validity
of preference studies, and
how can this be improved?
5 7 21,40,59,66,97
2. How can we merge
real-world data (eg, adherence data)
and stated preference studies?
4 6 14,48,49,56
Patient
characteristics
1. Which sociodemographic
patient characteristics
(eg, sex, age, education,
income, family, risk attitude,
and beliefs) affect preferences,
and how should we tailor these subgroups?
6 9 30,38,46,
55,56,97
2. Which disease-speciﬁc
patient characteristics
(eg, stage and severity of illness)
affect preferences, and how
should we tailor these subgroups?
6 9 46,55,56,
81,96,97
continued on next page
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Table 3. Continued
Category Topic # Issue N = 67* %† Article(s)
Practical
Resources 1. How can cost constraints of
preference studies be overcome?
13 19 25,30,37,41–43,53,
54,57–60,68
2. How can time constraints of
preference studies be overcome?
11 16 25,29,30,41–43,54,59,60,68,98
3. How can staff/expertise
constraints of preference
studies be overcome
(who should perform preference studies)?
6 9 25,29,42,60,67,68
4. How can location constraints of preference studies be
overcome?
1 1 30
QALY indicates quality adjusted life year; HTA, Health Technology Assessment.
*Absolute number of articles.
†Relative number of articles mentioning each issue (as % of 67 articles). Percentages do not add up to 100% because most studies mentioned multiple issues or because
of rounding error.
Figure 3. Relative occurrence of issues, per category of issues.
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non-HTA speciﬁc literature9,12 in which experts generally argue for
the use of patient preferences in healthcare research. According to
Ostermann et al.,12 important issues are internal and external
validity, reliability, and preference heterogeneity in addition to
evidence-based prediction of uptake and adherence. In a research
agenda concerning regulatory review of medical devices, Levitan
et al.9 stated that validity and reliability, the choice of method,
sample selection, patient-relevant outcomes and processes,
framing, patient education, and correcting for patient
characteristics were important issues to consider. Within the HTA
context, Mott10 prioritized issues about weighting patient
preferences in current HTA procedures. He discussed whether
patient preferences should be incorporated within the QALY or
beyond the QALY and proposed multiple-criteria decision analysis
as a new methodological approach to HTA. The challenges
mentioned by Facey et al.23 include the impact of preference
studies on HTA decisions, time and cost constraints, and how to
weight preference studies alongside clinical and cost-effectiveness
studies. The authors also strongly highlighted the need for patient
preference studies to be evidence based. Despite the fact that the
previously mentioned authors differed in their prioritization of
issues, all of the issues in their articles were also identiﬁed in our
review, advocating its inclusiveness.
Some aspects of this review require discussion. A ﬁrst
limitation is that articles outside the scope of our deﬁnitions may
have been overlooked for various reasons. As mentioned in some
of the included articles,25–28,36,49 patient preferences are not
clearly deﬁned, and therefore studies concerning this topic are not
easily retrievable. Furthermore, the integration of public
preferences is sometimes discussed alongside the integration of
patient preferences.28,30,34,35,44,53,61–68 Although it is an important
issue to address, it was not an explicit goal of this research to take
a stance on or provide an overview of whether to use patient,
public, or both preferences in HTA. For an overview of arguments
for and against public and patient preferences in health valuation,
other literature10,69–74 can be consulted. Other reasons for
potentially having overlooked important research questions that
are inherent to reviewing literature are publication lag or bias and
the inclusion of only English-language articles.
Second, the process of categorization should be interpreted
with caution. For pragmatic reasons, study characteristics and
issues were extracted by 1 researcher, followed by conﬁrmation by
2 other researchers. The categorization of issues was performed by2 researchers, followed by conﬁrmation by a third researcher, yet
the issues were subjectively categorized to put them into context.
There could be discrepancies between what was originally meant
by authors of the articles included in the analysis, how we
interpreted the issues, and how other researchers would interpret
them. In addition, we interpreted frequency of occurrence as a
way to measure priority. The broader the issue, the more it is
likely to occur; so it is possible that issues unintentionally became
weighted according to their speciﬁcity in the extraction process.
The current categorization is by no means intended to be
deﬁnitive. However, it is a systematically retrieved overview and,
we believe, an informative descriptive basis for a more extensive
prioritization of issues to advance the integration of patient
preferences in HTA. Other interesting research that goes beyond
the scope of this article could be in-depth analysis about how
knowledge accumulated on a particular issue or topic as listed in
this review. In addition, it might be interesting to research how
particular issues or topics trend together.
Thirdly, it should be noted that HTA studies vary in the degree
to which patient preferences are meaningful. According to the
articles included in this systematic review, integrating patient
preferences in HTA is mostly relevant for the following situations:
when there is no 1 treatment that is considered superior,14,25,26
when the beneﬁts of interventions are only marginal,14 when
uncertainty of the treatment outcome is high,4 when there are
1326 VALUE IN HEALTH NOVEMBER 2019multiple alternatives that vary largely in terms of risk-beneﬁt
trade-offs,4 when preferences of patients are expected to be very
heterogeneous,4 and when the treatment concerns a rare disease
that would beneﬁt from early HTA.46
Based on the literature and our interpretation of the data, we
recommend 2 areas for further research that are fundamental to
the advancement of integrating patient preferences in HTA. First,
as addressed in articles included in this review14,32,36,51,75 and
beyond,10,69,76 the discussion as to whether patient preferences
should be incorporated within the QALY or beyond the QALY is
essential to the integration of patient preferences in HTA. Second,
in agreement with articles included in this review32,45 and
broader literature,7,10,19,77–79 we recommend exploration of the
possibilities of using multiple-criteria decision analysis to
integrate patient preferences. Both of these procedural matters
relate to normative changes to current HTA procedures, hence
warranting further research. Other normative issues, such as
whose preferences to incorporate in HTA, concern a choice rather
than further research. To address the entire spectrum of issues
identiﬁed in this review, especially the normative issues, better
communication, collaboration, and consensus among the different
stakeholders is required.80,81
Conclusion
In line with the increasing use of patient preferences in
various medical contexts, the integration of patient preferences
in HTA is expected to contribute to better decision making and
to increase uptake, adherence, and patient satisfaction. So,
what is next for patient preferences in HTA? Methodological
and procedural issues were mentioned most; yet, the
large number of different issues advocates the overall
importance of a multi-stakeholder and holistic approach to the
integration of patient preferences in HTA. By providing a
contemporary overview of issues in the literature, this review
is an important ﬁrst step toward the integration of patient
preferences in HTA in a systematic and scientiﬁcally valid
manner. The next step requires coordination and collaboration
among the different stakeholders to reach consensus on the
way forward.
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